|
1
|
Pi-Sunyer X: The metabolic syndrome: how
to approach differing definitions. Med Clin North Am. 91:1025–1040.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gluckman PD, Hanson MA, Bateson P, et al:
Towards a new developmental synthesis: adaptive developmental
plasticity and human disease. Lancet. 373:1654–1657. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Cavali ML, Escrivão MA, Brasileiro RS
and Taddei JA: Metabolic syndrome: comparison of diagnosis
criteria. J Pediatr (Rio J). 86:325–330. 2010.(In Portuguese).
|
|
4
|
World Health Organization. Definition,
diagnosis and classification of diabetes mellitus and Diagnosis and
classification of diabetes mellitus[M]. WHO; Geneva: 1999
|
|
5
|
MS CDS ref-waiting for it in
English
|
|
6
|
Mogensen CE, Christensen CK and Vittinghus
E: The stages in diabetic renal disease. With emphasis on the stage
of incipient diabetic nephropathy. [J] Diabetes. 1983.32(suppl 2):
64–78
|
|
7
|
Ford ES, Giles WH and Dietz WH: Prevalence
of the metabolic syndrome among US adults: findings from the third
National Health and Nutrition Examination Survey. JAMA.
287:356–359. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hajat C and Shather Z: Prevalence of
metabolic syndrome and prediction of diabetes using IDF versus
ATPIII criteria in a Middle East population. Diabetes Res Clin
Pract. 98:481–486. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Riediger ND and Clara I: Prevalence of
metabolic syndrome in the Canadian adult population. CMAJ.
183:E1127–E1134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jia WP, Xiang KS, Chen L, et al: A
comparison of the application of two working definitions of
metabolic syndrome in Chinese population. Zhonghua Yi Xue Za Zhi.
84:534–538. 2004.PubMed/NCBI
|
|
11
|
Li R, Lv M, Xiao F, et al: Investigation
on the prevalence rate of metabolic syndrome among elderly in 5
Chinese urban communities. Xian Dai Yu Fang Yi Xue. 7:460–462.
2012.
|
|
12
|
de Cavali ML, Escrivão MA, Brasileiro RS
and Taddei JA: Metabolic syndrome: comparison of diagnosis
criteria. J Pediatr (Rio J). 86:325–330. 2010.
|
|
13
|
Martins D, Ani C, Pan D, Ogunyemi O and
Norris K: Renal dysfunction, metabolic syndrome and cardiovascular
disease mortality. J Nutr Metab. 2010:1671622010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Saito I, Iso H, Kokubo Y, Inoue M and
Tsugane S: Metabolic syndrome and all-cause and cardiovascular
disease mortality: Japan Public Health Center-based Prospective
(JPHC) Study. Circ J. 73:878–884. 2009. View Article : Google Scholar
|
|
15
|
Ginter E and Simko V: Global prevalence
and future of diabetes mellitus. Adv Exp Med Biol. 771:35–41.
2012.PubMed/NCBI
|
|
16
|
Li S, Rao X and Tan X: The pathogenesis of
diabetic retinopathy and clinical research progress. Bai Qiu En Yi
Xue Yuan Xue Bao. 9:118–120. 2011.
|
|
17
|
Chen R and Guan C: Prevalence and risk
factors analysis of chronic complications in tie in patients with
Type 2 diabetes mellitus. Xin Nao Xue Guan Bing Fang Zhi.
11:4292011.
|
|
18
|
McNeill AM, Rosamond WD, Girman CJ, et al:
The metabolic syndrome and 11-year risk of incident cardiovascular
disease in the atherosclerosis risk in communities study. Diabetes
Care. 28:385–390. 2005.PubMed/NCBI
|
|
19
|
Isomaa B, Henricsson M, Almgren P, et al:
The metabolic syndrome influences the risk of chronic complications
in patients with type II diabetes. Diabetologia. 44:1148–1154.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
No authors listed. Intensive blood-glucose
control with sulphonylureas or insulin compared with conventional
treatment and risk of complications in patients with type 2
diabetes. UK Prospective Diabetes Study (UKPDS) group. Lancet.
352:837–853. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee IT, Chiu YF, Hwu CM, et al: Central
obesity is important but not essential component of the metabolic
syndrome for predicting diabetes mellitus in a hypertensive
family-based cohort. Results from the Stanford Asia-pacific program
for hypertension and insulin resistance (SAPPHIRe) Taiwan follow-up
study. Cardivasc Diabetol. 11:432012.
|
|
22
|
Gallagher EJ, Leroith D and Karnieli E:
The metabolic syndrome - from insulin resistance to obesity and
diabetes. Med Clin North Am. 95:855–873. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Barth RJ: Insulin resistance, obesity and
the metabolic syndrome. S D Med Spec No. 22–27. 2011.
|
|
24
|
No authors listed. The effect of intensive
treatment of diabetes on the development and progression of
long-term complications in insulin-dependent diabetes mellitus. The
Diabetes Control and Complications Trial Research group. N Engl J
Med. 329:977–986. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Duran-Perez EG, Almeda-Valdes P,
Cuevas-Ramos D, Campos-Barrera E, Muñoz-Hernandez L and Gomez-Perez
FJ: Treatment of metabolic syndrome slows progression of diabetic
nephropathy. Metab Syndr Relat Disord. 9:483–489. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Maric C and Hall JE: Obesity, metabolic
syndrome and diabetic nephropathy. Contrib Nephrol. 170:28–35.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thorn LM, Forsblom C, Wadén J, Saraheimo
M, Tolonen N, Hietala K and Groop PH; Finnish Diabetic Nephropathy
(FinnDiane) Study Group. Metabolic syndrome as a risk factor for
cardiovascular disease, mortality and progression of diabetic
nephropathy in type 1 diabetes. Diabetes Care. 32:950–952. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Martínez Castelao A: Advances in diabetes
mellitus, diabetic nephropathy, metabolic syndrome and
cardio-vascular-renal risk. Nefrologia. 28(Suppl 5): 79–84.
2008.(In Spanish).
|
|
29
|
Raman R, Gupta A, Pal SS, Ganesan S,
Venkatesh K, Kulothungan V and Sharma T: Prevalence of Metabolic
Syndrome and its influence on microvascular complications in the
Indian population with Type 2 Diabetes Mellitus. Sankara Nethralaya
Diabetic Retinopathy Epidemiology And Molecular Genetic Study
(SN-DREAMS, report 14). Diabetol Metab Syndr. 2:672010. View Article : Google Scholar
|
|
30
|
Sass DA, Chang P and Chopra KB:
Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci.
50:171–180. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kolovou GD, Anagnostopoulou KK and
Cokkinos DV: Pathophysiology of dyslipidaemia in the metabolic
syndrome. Postgrad Med J. 81:358–366. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Orchard TJ, Temprosa M, Goldberg R,
Haffner S, Ratner R, Marcovina S and Fowler S; Diabetes Prevention
Program Research Group. The effect of metformin and intensive
lifestyle intervention on the metabolic syndrome: the Diabetes
Prevention Program randomized trial. Ann Intern Med. 142:611–619.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Muzio F, Mondazzi L, Sommariva D and
Branchi A: Long-term effects of low-calorie diet on the metabolic
syndrome in obese nondiabetic patients. Diabetes Care.
28:1485–1486. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tuttle KR, Bakris GL, Toto RD, McGill JB,
Hu K and Anderson PW: The effect of ruboxistaurin on nephropathy in
type 2 diabetes. Diabetes Care. 28:2686–2690. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hanford LE, Enghild JJ, Valnickova Z, et
al: Purification and characterization of mouse soluble receptor for
advanced glycation end products (sRAGE). J Biol Chem.
279:50019–50024. 2004. View Article : Google Scholar : PubMed/NCBI
|
